Immunotherapeutic approaches for cancer therapy: An updated review - PubMed

Review

Immunotherapeutic approaches for cancer therapy: An updated review

Tohid Kazemi et al. Artif Cells Nanomed Biotechnol. 2016 May.

Free article

Abstract

In spite of specific immune effector mechanisms raised against tumor cells, there are mechanisms employed by the tumor cells to keep them away from immune recognition and elimination; some of these mechanisms have been identified, while others are still poorly understood. Manipulation or augmentation of specific antitumor immune responses are now the preferred approaches for treatment of malignancies, and traditional therapeutic approaches are being replaced by the use of agents which potentiate immune effector mechanisms, broadly called "immunotherapy". Cancer immunotherapy is generally classified into two main classes including active and passive methods. Interventions to augment the immune system of the patient, for example, vaccination or adjuvant therapy, actively promote antitumor effector mechanisms to improve cancer elimination. On the other hand, administration of specific monoclonal antibodies (mAbs) against different tumor antigens and adoptive transfer of genetically-modified specific T cells are currently the most rapidly developing approaches for cancer targeted therapy. In this review, we will discuss the different modalities for active and passive immunotherapy for cancer.

Keywords: cancer; cancer stem cell; dendritic cell; immunotherapy; monoclonal antibody; vaccination.

Similar articles

• Generation of tumor-specific T-cell therapies.

  Morris E, Hart D, Gao L, Tsallios A, Xue SA, Stauss H. Morris E, et al. Blood Rev. 2006 Mar;20(2):61-9. doi: 10.1016/j.blre.2005.05.001. Epub 2005 Jun 22. Blood Rev. 2006. PMID: 15978709 Review.

• Antitumor Antibodies Can Drive Therapeutic T Cell Responses.

  Wittrup KD. Wittrup KD. Trends Cancer. 2017 Sep;3(9):615-620. doi: 10.1016/j.trecan.2017.07.001. Epub 2017 Jul 29. Trends Cancer. 2017. PMID: 28867165 Free PMC article. Review.

• Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy.

  Anguille S, Smits EL, Bryant C, Van Acker HH, Goossens H, Lion E, Fromm PD, Hart DN, Van Tendeloo VF, Berneman ZN. Anguille S, et al. Pharmacol Rev. 2015 Oct;67(4):731-53. doi: 10.1124/pr.114.009456. Pharmacol Rev. 2015. PMID: 26240218 Review.

• Bi-specific antibody therapy for the treatment of cancer.

  Withoff S, Helfrich W, de Leij LF, Molema G. Withoff S, et al. Curr Opin Mol Ther. 2001 Feb;3(1):53-62. Curr Opin Mol Ther. 2001. PMID: 11249732 Review.

• Immunotherapeutic approaches for hematologic malignancies.

  Caligiuri MA, Velardi A, Scheinberg DA, Borrello IM. Caligiuri MA, et al. Hematology Am Soc Hematol Educ Program. 2004:337-53. doi: 10.1182/asheducation-2004.1.337. Hematology Am Soc Hematol Educ Program. 2004. PMID: 15561691 Review.

Cited by

• PRUNE2 inhibits progression of colorectal cancer in vitro and in vivo.

  Li T, Huang S, Yan W, Zhang Y, Guo Q. Li T, et al. Exp Ther Med. 2022 Feb;23(2):169. doi: 10.3892/etm.2021.11092. Epub 2021 Dec 27. Exp Ther Med. 2022. PMID: 35069850 Free PMC article.

• Cancer immunotherapy: the beginning of the end of cancer?

  Farkona S, Diamandis EP, Blasutig IM. Farkona S, et al. BMC Med. 2016 May 5;14:73. doi: 10.1186/s12916-016-0623-5. BMC Med. 2016. PMID: 27151159 Free PMC article. Review.

• Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.

  Hassannia H, Ghasemi Chaleshtari M, Atyabi F, Nosouhian M, Masjedi A, Hojjat-Farsangi M, Namdar A, Azizi G, Mohammadi H, Ghalamfarsa G, Sabz G, Hasanzadeh S, Yousefi M, Jadidi-Niaragh F. Hassannia H, et al. Immunology. 2020 Jan;159(1):75-87. doi: 10.1111/imm.13126. Epub 2019 Oct 24. Immunology. 2020. PMID: 31587253 Free PMC article.

• Genomics of adult and pediatric solid tumors.

  Rahal Z, Abdulhai F, Kadara H, Saab R. Rahal Z, et al. Am J Cancer Res. 2018 Aug 1;8(8):1356-1386. eCollection 2018. Am J Cancer Res. 2018. PMID: 30210910 Free PMC article. Review.

• Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model.

  Barshidi A, Karpisheh V, Noukabadi FK, Kiani FK, Mohammadi M, Afsharimanesh N, Ebrahimi F, Kiaie SH, Navashenaq JG, Hojjat-Farsangi M, Zolbanin NM, Mahmoodpoor A, Hassannia H, Nami S, Jalali P, Jafari R, Jadidi-Niaragh F. Barshidi A, et al. Pharm Res. 2022 Aug;39(8):1851-1866. doi: 10.1007/s11095-022-03297-9. Epub 2022 Jun 17. Pharm Res. 2022. PMID: 35715669 Retracted.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon